15 min
Arrhythmic mitral valve prolapse: where do we stand? CardioPractice Cardio Talk
-
- Medicine
With Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.
In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.
With Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.
In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.
15 min